title: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
abstract: Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
authors.affiliation: Department of Obstetrics and Gynecology, J.W. Goethe-University Hospital, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
authors.forename: Manfred
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Hortobagyi
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: Suzy
authors.initials: S
authors.lastname: Scholl
authors.forename: Andreas
authors.initials: A
authors.lastname: Makris
authors.forename: Pinuccia
authors.initials: P
authors.lastname: Valagussa
authors.forename: Jens-Uwe
authors.initials: JU
authors.lastname: Blohmer
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Eiermann
authors.forename: Raimund
authors.initials: R
authors.lastname: Jackesz
authors.forename: Walter
authors.initials: W
authors.lastname: Jonat
authors.forename: Annette
authors.initials: A
authors.lastname: Lebeau
authors.forename: Sibylle
authors.initials: S
authors.lastname: Loibl
authors.forename: William
authors.initials: W
authors.lastname: Miller
authors.forename: Sigfried
authors.initials: S
authors.lastname: Seeber
authors.forename: Vladimir
authors.initials: V
authors.lastname: Semiglazov
authors.forename: Roy
authors.initials: R
authors.lastname: Smith
authors.forename: Rainer
authors.initials: R
authors.lastname: Souchon
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
authors.forename: Michael
authors.initials: M
authors.lastname: Untch
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone